10-K/A: Shattuck Labs Files Amendment to 2024 Annual Report, Providing Detailed Information on Directors, Executive Compensation, and Corporate Governance

Shattuck Labs files an amendment to its 2024 Annual Report on Form 10-K/A to include information required by Items 10 through 14 of Part III, covering directors, executive compensation, security ownership, related transactions, and principal accountant fees.

Summary

• Shattuck Labs, Inc. filed Amendment No. 1 on Form 10-K/A to its 2024 Annual Report to include information previously omitted regarding Items 10 through 14 of Part III of Form 10-K.
• The amendment includes details on the company's directors, executive officers, corporate governance, executive compensation, security ownership, related transactions, and principal accountant fees and services.
• The Board of Directors manages the business affairs and is divided into three classes with staggered three-year terms.
• The company has adopted a Code of Business Conduct and Ethics and insider trading policies.
• The Audit Committee is comprised solely of independent directors, with Helen M. Boudreau qualifying as an audit committee financial expert.
• The report details the compensation of the named executive officers (NEOs) for 2024, including salary, stock awards, option awards, and non-equity incentive plan compensation.
• The NEOs for 2024 are Dr. Taylor Schreiber (Chief Executive Officer), Mr. Andrew R. Neill (Chief Financial Officer), and Dr. Arunthathy Nirmalini (Lini) Pandite (Chief Medical Officer).
• The company has employment agreements with each of the NEOs, providing for base salary, bonus eligibility, and participation in employee benefit plans.
• The report outlines the security ownership of certain beneficial owners, management, and related stockholder matters as of April 1, 2025.
• The company has a related person transaction policy for the identification, review, and approval of transactions exceeding $120,000 involving related persons.
• The Board has determined that all directors, except Dr. Schreiber, are independent under Nasdaq listing rules.
• KPMG LLP has served as the company's independent auditor since 2018, with audit fees of $760,000 for 2024.

Sentiment

Score: 7

Explanation: The document is a standard regulatory filing, presenting factual information about the company's governance, executive compensation, and ownership structure. The sentiment is neutral to slightly positive, reflecting the company's adherence to regulatory requirements and established corporate governance practices.

Positives

• The company has a Code of Business Conduct and Ethics and insider trading policies in place.
• The Audit Committee is comprised solely of independent directors.
• The company has a related person transaction policy to ensure fair dealings.
• The Board has determined that the majority of directors are independent, ensuring objective oversight.
• The company offers a 401(k) plan with matching contributions for employees.
• The company has adopted a Rule 10D-1 Clawback Policy.

Negatives

• One Form 4 reporting four transactions related to the grants of restricted stock units and stock options and a sale of common stock was filed late with respect to Mr. Neill.
• One Form 4 reporting three transactions related to the grants of restricted stock units and stock options was filed late with respect to each of Ms. DeYoung and Dr. Pandite.
• One Form 4 reporting two transactions related to the grants of restricted stock units and stock options was filed late with respect to each of Dr. Shukla and Mr. Stout.

Risks

• The company's success depends on the clinical development of SL-172154 and other preclinical compounds.
• The company faces risks related to manufacturing processes and corporate and business development objectives.
• The company is subject to the risk of potential conflicts of interest in related party transactions.
• The company is subject to the risk of potential accounting restatements.

Future Outlook

The document does not contain specific forward-looking statements beyond the routine operation of existing compensation and governance policies.

Industry Context

The document provides insight into the corporate governance and executive compensation practices of a publicly traded biopharmaceutical company, Shattuck Labs, which is useful for comparison against industry peers. The details on board composition, committee structures, and compensation policies reflect standard practices for companies in the biotechnology sector.

Comparison to Industry Standards

• The board structure with staggered terms is a common practice among publicly traded companies to ensure continuity and experience.
• The compensation packages for the NEOs, including salary, stock options, and bonuses, are typical for executives in the biopharmaceutical industry.
• The presence of an audit committee with independent directors and a financial expert aligns with regulatory requirements and best practices for corporate governance.
• The related person transaction policy is a standard measure to prevent conflicts of interest and ensure fair dealings, similar to policies at companies like Amgen (AMGN) and Gilead Sciences (GILD).
• The use of KPMG as the independent auditor is a common choice among publicly traded companies, reflecting a preference for established and reputable accounting firms.

Corporate Governance

Related Party Transactions

• On December 21, 2023, the Company entered into a Securities Purchase Agreement with certain entities affiliated with Redmile (the Purchasers), relating to the purchase of pre-funded warrants to purchase 3,100,823 shares of common stock at a purchase price of $6.4499 per pre-funded warrant, for aggregate gross proceeds of $19,999,998.30, before deducting offering expenses (the Private Placement).
• Mr. Lee, a director of the Company, serves as Managing Director of Redmile.
• In connection with the foregoing, on December 21, 2023, the Company also entered into a Registration Rights Agreement (the Registration Rights Agreement) with the Purchasers, pursuant to which the Company granted the Purchasers certain registration rights with respect to the shares of common stock issuable upon the exercise of the pre-funded warrants.

Stakeholder Impact

• Shareholders: The report provides transparency regarding executive compensation, corporate governance, and security ownership, which is important for making informed investment decisions.
• Employees: The report outlines the compensation structure for executives and the availability of benefits such as the 401(k) plan, which can impact employee morale and retention.
• Customers: The report does not directly impact customers, as it primarily focuses on internal governance and financial matters.
• Suppliers: The report does not directly impact suppliers, as it primarily focuses on internal governance and financial matters.
• Creditors: The report provides information about the company's financial health and governance practices, which can influence lending decisions.

Next Steps

• The company will continue to operate under its established corporate governance policies.
• The company will continue to execute its clinical development and business strategies.
• The company will file its definitive proxy statement at a later date.

Key Dates

Keywords

executive compensation, corporate governance, directors, security ownership, related transactions, audit fees, Shattuck Labs, Form 10-K/A